PHAXIAM Therapeutics S.A. Total Liabilities
PHAXIAM Therapeutics S.A. total liabilities. Based on the latest financial reports, PHAXIAM Therapeutics S.A. (PHXM) has total liabilities worth €23.66 Million EUR (≈ $27.66 Million USD) as of June 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check PHXM financial resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of PHAXIAM Therapeutics S.A. (2010–2023)
Total liabilities of PHAXIAM Therapeutics S.A. from 2010 to 2023. This chart illustrates how PHAXIAM Therapeutics S.A.'s total liabilities have evolved over time, based on quarterly financial data. Explore investment intensity of PHAXIAM Therapeutics S.A. to see how much of total assets are deployed in long-term investments.
PHAXIAM Therapeutics S.A. Competitors by Total Liabilities
The table below lists competitors of PHAXIAM Therapeutics S.A. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Boardwalktech Software Corp
V:BWLK
|
Canada | CA$5.64 Million |
|
Moolec Science SA Ordinary Shares
NASDAQ:MLEC
|
USA | $88.21 Million |
|
New Energy Metals Corp
V:ENRG
|
Canada | CA$306.96K |
|
Avation PLC
LSE:AVAP
|
UK | GBX762.44 Million |
|
BioNeutra Global Corp
V:BGA
|
Canada | CA$21.81 Million |
|
Jet.AI Inc.
NASDAQ:JTAI
|
USA | $3.71 Million |
|
Sarawak Cable Bhd
KLSE:5170
|
Malaysia | RM466.66 Million |
|
Value & Income Trust
LSE:VIP
|
UK | GBX51.79 Million |
Liability Composition Analysis (2010–2023)
This chart breaks down PHAXIAM Therapeutics S.A.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see PHXM total assets.
Liquidity & Leverage Metrics
PHAXIAM Therapeutics S.A. Total Liabilities Ratios Explained
PHAXIAM Therapeutics S.A. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.38 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.09 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.53 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.60 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how PHAXIAM Therapeutics S.A.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for PHAXIAM Therapeutics S.A. (2010–2023)
The table below shows the annual total liabilities of PHAXIAM Therapeutics S.A. from 2010 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | €25.70 Million ≈ $30.04 Million |
+15.10% |
| 2022-12-31 | €22.32 Million ≈ $26.10 Million |
-49.17% |
| 2021-12-31 | €43.92 Million ≈ $51.35 Million |
-18.45% |
| 2020-12-31 | €53.86 Million ≈ $62.97 Million |
+63.29% |
| 2019-12-31 | €32.99 Million ≈ $38.56 Million |
+48.33% |
| 2018-12-31 | €22.24 Million ≈ $26.00 Million |
+60.66% |
| 2017-12-31 | €13.84 Million ≈ $16.18 Million |
+48.38% |
| 2016-12-31 | €9.33 Million ≈ $10.91 Million |
+58.87% |
| 2015-12-31 | €5.87 Million ≈ $6.86 Million |
+22.79% |
| 2014-12-31 | €4.78 Million ≈ $5.59 Million |
+9.63% |
| 2013-12-31 | €4.36 Million ≈ $5.10 Million |
-69.22% |
| 2012-12-31 | €14.17 Million ≈ $16.57 Million |
+106.96% |
| 2011-12-31 | €6.85 Million ≈ $8.00 Million |
+165.59% |
| 2010-12-31 | €2.58 Million ≈ $3.01 Million |
-- |
About PHAXIAM Therapeutics S.A.
PHAXIAM Therapeutics S.A., a clinical-stage biopharmaceutical company, focuses on developing bacteriophage-based therapies for severe resistance infections in France. The company develops and commercializes red cell-based therapies for cancers and orphan diseases. It develops anti-infectious therapies based on the use of bacteriophages (phages) to treat infections caused by Escherichia coli (E.co… Read more